146 related articles for article (PubMed ID: 35093868)
1. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
2. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
4. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
5. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
[TBL] [Abstract][Full Text] [Related]
8. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
[TBL] [Abstract][Full Text] [Related]
11. Methylation of gene CHFR promoter in acute leukemia cells.
Gong H; Liu W; Zhou J; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
[TBL] [Abstract][Full Text] [Related]
12. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
14. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
[TBL] [Abstract][Full Text] [Related]
18. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
20. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.
Hu SL; Huang DB; Sun YB; Wu L; Xu WP; Yin S; Chen J; Jiang XD; Shen G
Med Oncol; 2011 Jun; 28(2):447-54. PubMed ID: 20300977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]